Printer Friendly

DEPRENYL USA CLASS A WARRANTS MAYBE EXERCISED UNTIL APRIL 19, 1993

 PARSIPPANY, N.J., Feb. 2 /PRNewswire/ -- Deprenyl USA, Inc. (NASDAQ: DUSA) wishes to confirm that its Class A Warrants will expire on April 19, 1993 as stated in its prospectus.
 Deprenyl USA is a development stage company established to develop prescription pharmaceutical products for worldwide markets initially in the United States and Canada, primarily in the field of photodynamic therapy.
 Common stock and warrants are traded on NASDAQ under the symbols DUSA and DUSAW. They also trade on the Toronto Stock Exchange under the symbols DPU and DPU.WT.
 -0- 2/2/93
 /CONTACT: In Toronto, D. Geoffrey Shulman, M.D., president & CEO, 416-537-1070 or 416-537-4372, or fax, 416-537-0258; In New Jersey, Joseph P. Castelli, vice president, 201-299-9070 or fax, 201-335-0372, both of Deprenyl USA, Inc.; or Jim Tolan or Nicholas Biro of O'Connor Biro & Associates, 708-498-2284 or fax, 708-498-3144, for Deprenyl USA/
 (DUSA)


CO: Deprenyl USA, Inc. ST: New Jersey IN: MTC SU:

SM -- NY092 -- 2006 02/02/93 15:18 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 2, 1993
Words:163
Previous Article:THOR ANNOUNCES RECORD THREE AND SIX MONTHS SALES; JUMPS TO NO. 3 IN MOTOR HOMES; MARKET SHARE IN TRAVEL TRAILERS AND FIFTH WHEELS UP
Next Article:INTELLICALL ANNOUNCES TENTATIVE SETTLEMENT OF STOCKHOLDER LAWSUIT
Topics:


Related Articles
DEPRENYL RESEARCH COMMENTS ON STOCK PRICE
DEPRENYL USA ANNOUNCES CONDITIONAL LISTING ON TORONTO STOCK EXCHANGE
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE
DEPRENYL RESEARCH LTD. & BONE HEALTH INC. TO AWAIT FULL ANALYSIS OF CLINICAL TRIALS BEFORE ISSUING FINAL AMENDMENTS TO PROSPECTUS
BONE HEALTH INC. WARRANTS EXTENDED TO SEPT. 30, 1993
CORTEX EXTENDS CLASS A, CLASS B AND CLASS C WARRANTS
CORTEX EXTENDS CLASS A, CLASS B AND CLASS C WARRANTS
DALTEX MEDICAL SCIENCES, INC. EXTENDS THE EXPIRATION DATES OF ITS CLASS A AND CLASS B WARRANTS
DRAXIS RECEIVES CLEARANCE FOR FINAL PROSPECTUS; APPROVAL ALLOWS ISSUANCE OF 3,000,000 COMMON SHARES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters